Company profile for Celularity

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ a...
Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
33 Technology Drive Warren, NJ 07059
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/30/3177365/0/en/Celularity-and-DefEYE-Inc-Partner-to-Advance-Growth-of-Regenerative-Therapies-in-Eye-Care.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/14/3166225/0/en/Celularity-Announces-Peer-Reviewed-Publication-of-Phase-2-Clinical-Trial-Results-Demonstrating-the-Safety-and-Efficacy-of-Human-Placenta-Derived-Cells-PDA-002-for-Diabetic-Foot-Ulc.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/08/22/3138055/0/en/Celularity-Receives-Nasdaq-Notice-Regarding-Form-10-Q.html

GLOBENEWSWIRE
22 Aug 2025

https://www.globenewswire.com/news-release/2025/08/18/3134978/0/en/Celularity-Completes-Major-Balance-Sheet-Restructuring-Retires-All-41-6-Million-in-Senior-Secured-Debt.html

GLOBENEWSWIRE
18 Aug 2025

https://www.globenewswire.com/news-release/2025/07/09/3112554/0/en/Celularity-Fountain-Life-Announce-Partnership-to-Deliver-Stem-Cell-Therapies-Under-New-Florida-Law.html

GLOBENEWSWIRE
09 Jul 2025

https://www.globenewswire.com/news-release/2025/07/01/3108312/0/en/Celularity-Hails-New-Florida-Law-Opening-Patient-Access-to-Stem-Cell-Therapies.html

GLOBENEWSWIRE
01 Jul 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty